Andrey Ignatenko

Andrey’s experience also includes advising a number of charities and other nonprofits on corporate and corporate governance matters, including those pertaining to the most complex forms.

Prior to joining Morgan Lewis, Andrey served as a paralegal in the corporate practice of another international law firm resident in Moscow. He is fluent in Russian and English.

M&A, Joint Ventures, Divestments and Corporate Restructurings

• The Russia-China Investment Fund (RCIF), established by the Russian Direct Investment Fund and China Investment Corporation, on legal due diligence and associated advice in respect of US $21 mln investment together with SberInvest in Eruditor Group holding, owner of the leading Russian professional services marketplace Profi and Zoon information service
• The Russia-China Investment Fund (RCIF) on the establishment and joint development of pharmaceutical holding company Binnopharm Group, one of the three largest pharmaceutical manufacturers in Russia
• A global manufacturing company on the restructuring of its Russian subsidiary and related compliance, corporate, and commercial matters
• A leading Russian producer of green chemistry products in connection with its exit from a joint venture with one of the leading Russian companies in the pulp and paper industry
• A private US medical device company focused on the development of hyperspectral imaging solutions on its exit from a joint venture with a foreign venture capital fund
• A leading Russian pharmaceutical company in connection with its strategic partnership with a leading medical equipment manufacturer in respect of manufacturing and distribution of diagnostic imaging systems in Russia and the Commonwealth of Independent States (CIS)
• One of the largest private transportation and logistics holding companies in Russia that specializes in port logistics comprising marine terminals (grain, containers, port services, and other assets) in its acquisition through a public auction of 50% plus two shares in the largest Russian intermodal container operator that handles container cargo throughout Europe and Asia; we guided the client through the auction process, due diligence, and bank financing matters and also assisted with analysis on regulatory clearances that may be required in Russia and 12 other jurisdictions; this transaction has been recognized as the largest privatization deal in Russia in 2019
• A subsidiary of a Russian high-technology pharmaceutical company in connection with a strategic partnership with the largest manufacturer of scientific instruments for the scientific industry over establishing local manufacturing of radio therapeutic equipment
• A consortium of sovereign investment funds on the private equity investment in a holding company that owns a leading Russian pharmaceutical manufacturer
• A multinational health and personal care products company on the sale of its Russian distribution company, which sells a wide range of traditional and homeopathic over-the-counter pharmaceutical products, to a European buyer; in connection with the sale, the parties also entered into a long-term manufacturing and supply agreement
• A leading global financial services firm on the sale of a minority stake in a large Russian bank to principals of one of Russia’s largest private banks
• The mass media division of one of the world’s largest media conglomerates focused primarily on cinema and cable television on a joint venture (which broadcast and distributed more than 10 pay television channels in Russia) with a Russian company related to a prominent Russian business group
• A leading provider of global mobile satellite services on the sale of its Russian subsidiary
• One of the largest US diversified media and information groups on the restructuring of its Russian publishing joint venture and the negotiation of a joint venture with a Russian partner to comply with a Russian law imposing a 20% cap on non-Russian (foreign) investments in Russian media companies; the business published popular magazines in the Russian market and neighboring countries
• A global manufacturing supply company on its acquisition of a privately held bearings company business in Russia
• An Italian engineering company on the acquisition of a stake in a Russian state-owned engineering company
• A large US company on a joint venture with the Kazakhstan national railway company and a Russian partner to produce diesel engines in Kazakhstan

Regulatory & Compliance

• An American private investment firm on a wide range of regulatory issues in connection with its $2.1 billion acquisition of a medical devices division of a leading pharmaceutical and medical devices company, including on reissuance of marketing authorizations for the whole portfolio of products by the Russian Federal Service for Supervision of Public Health and Social Development
• A leading global pharmaceutical company focused on specialist therapeutic areas of oncology, neurodegenerative diseases, fertility, endocrinology, cardiometabolic care, and general medicine products on a distribution and cooperation agreement with a Russian distributor
• A global biopharmaceutical company on the localization of its product manufacturing
• A European manufacturer of optical medical devices on obtaining necessary regulatory approvals for the distribution of its products in Russia, including approvals for clinical trials
• A global biopharmaceutical company that develops and delivers life-transforming therapies for patients with rare, life-threatening diseases on regulatory matters, including the inclusion of certain of the company’s drugs on the Russian vital and essential drugs list
• A global biopharmaceutical company on regulatory pathways for the approval of biosimilar products
• A global pharmaceutical company specializing in brain diseases on a master license and distribution agreement with a Russian distributor, including counseling on marketing campaigns
• A global healthcare company manufacturing branded generic pharmaceuticals, medical devices, and nutrition products on anticounterfeiting issues in Russia and the strategic development of a trademark portfolio in Russia and the CIS
• A global biopharmaceutical company on compliance with rules for pharmaceutical marketing and distribution in Russia involving samples, company visits, gifts, and entertainment
• An international television network on arrangements to cover the XXII Olympic Winter Games in Sochi

Antitrust & Competition

• A foreign pharmaceutical company that develops and delivers life-transforming therapies for patients with rare, life-threatening diseases on market dominance and other applicable competition law requirements in connection with the entry into a distributorship agreement with its local partner for commercialization of two brand new orphan drugs
• A subsidiary of a Russian high-technology pharmaceutical company on Russian competition law issues in connection with a strategic partnership with the largest manufacturer of scientific instruments for the scientific industry over establishing local manufacturing of radio therapeutic equipment
• A global producer of high-tech specialty chemical products on Russian competition matters for the acquisition of a major developer and distributor of innovative chemical solutions for the agroscience, health, and nutrition science markets
• A Russian high-technology pharmaceutical company on a variety of competition law and merger clearance issues in connection with its strategic partnership with a Japanese producer of medical systems, including assistance with preparation and negotiation of the distributorship agreement, joint venture agreement, technology license agreement, supply agreement for product kits, and other transaction documents
• Heritage Capital on obtaining a merger clearance in Russia for the acquisition of a controlling interest in luxury travel company Abercrombie & Kent Group of Companies S.A., and a strategic partnership with Geoffrey J.W. Kent, its founder, chairman, and CEO
• A consortium of sovereign investment funds on the merger control and foreign investments law aspects of its investment into the pharmaceutical holding created by a prominent Russian industrial group and a major Russian state-owned bank